{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:55:24Z","timestamp":1774061724464,"version":"3.50.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,25]]},"abstract":"<jats:p>Recently, there has been an increase of publications on super-responders to biologic therapy for psoriasis.In this study, we aimed to contribute to this growing area of research by (i) synthesizing the different definitions of super-responders currently being used in psoriasis literature; and (ii) evaluating the impact of these different definitions on the composition of the super-responder group.<\/jats:p>","DOI":"10.1093\/bjd\/ljad280","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T19:36:38Z","timestamp":1692387398000},"page":"621-622","source":"Crossref","is-referenced-by-count":18,"title":["How to define a \u2018super-responder\u2019 to biologics in psoriasis studies"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-353X","authenticated-orcid":false,"given":"Sarah E","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2673","authenticated-orcid":false,"given":"Juul M P A","family":"van den Reek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-8294","authenticated-orcid":false,"given":"Marieke M B","family":"Seyger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"Elke M G J","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen"},{"name":"Radboud University , Nijmegen , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"2023102707082070300_ljad280-B1","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707082070300_ljad280-B2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707082070300_ljad280-B3","article-title":"Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives","volume":"12","author":"Ruiz-Villaverde","year":"2022","journal-title":"Life (Basel)"},{"key":"2023102707082070300_ljad280-B4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1080\/09546634.2021.1898528","article-title":"Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Feldman","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2023102707082070300_ljad280-B5","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14731","article-title":"\u201cSuperresponders\u201d at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors","author":"Mastorino","year":"2022","journal-title":"Exp Dermatol"},{"key":"2023102707082070300_ljad280-B6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707082070300_ljad280-B7","doi-asserted-by":"crossref","first-page":"e364\u20137","DOI":"10.1111\/jdv.15659","article-title":"High-resolution HLA typing identifies a new \u2018super responder\u2019 subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02\/HLA-C*04, in response to ustekinumab","volume":"33","author":"Talamonti","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023102707082070300_ljad280-B8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert Opin Biol Ther"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad280\/51364380\/ljad280.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/621\/52625450\/ljad280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/621\/52625450\/ljad280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:10:02Z","timestamp":1698390602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/5\/621\/7245983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":8,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,18]]},"published-print":{"date-parts":[[2023,10,25]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad280","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,8,18]]}}}